Open an account

Molecular Partners AG

MOLN · SWISS

$3.67+$0.0608 (+1.68%)TodayMarket closed ·
Prev close $3.61

MOLN analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 7 analysts

Average $12.95 (+252.9% upside)

Low
$8.03
Now
$3.67
High
$19.27

Upgrades and downgrades

The latest rating actions, newest first

MOLN analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Apr 22, 2026MaintainsBuy
HC Wainwright & Co.Mar 16, 2026MaintainsBuy
HC Wainwright & Co.Jan 27, 2026InitiatesBuy
JP MorganDec 8, 2025MaintainsNeutral

The case for and against

Updated Jul 14, 2026

Bull case

Molecular Partners is well-positioned in the competitive landscape of proprietary molecular therapeutics, as evidenced by Zai Lab's agreements for DLL3-targeted ADC development with Amgen and Boehringer Ingelheim, and Daiichi Sankyo's licensing of MP0423. Preclinical data for MP0712 and MP0726 support its potential in the rapidly growing field of radioligand therapy, and we expect strong revenue generation (approximately $298M) from MP0712 in treating SCLC and NETs. Additionally, ongoing efforts to improve operational efficiency and profitability, such as AbbVie's licensing of alveltamig, are a positive indicator for the company's long-term success in the market.

Bear case

Molecular Partners is currently collaborating with Orano Med on ten potential programs, and even though they have had some initial success in pre-clinical and clinical development, the company has never been profitable and there is no guarantee that it will ever become profitable. Additionally, the biopharma industry is inherently volatile, and the company may face significant regulatory challenges with their treatments.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.